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OBJECTIVE—The optimal treatment of hyperglycemia in general surgical patients with type
2 diabetes mellitus is not known.
RESEARCH DESIGN AND METHODS—This randomized multicenter trial compared
the safety and efﬁcacy of a basal-bolus insulin regimen with glargine once daily and glulisine
before meals (n = 104) to sliding scale regular insulin (SSI) four times daily (n = 107) in patients
withtype2diabetesmellitusundergoinggeneralsurgery.Outcomesincludeddifferencesindaily
blood glucose (BG) and a composite of postoperative complications including wound infection,
pneumonia, bacteremia, and respiratory and acute renal failure.
RESULTS—The mean daily glucose concentration after the 1st day of basal-bolus insulin and
SSI was 145 6 32 mg/dL and 172 6 47 mg/dL, respectively (P , 0.01). Glucose readings ,140
mg/dL were recorded in 55% of patients in basal-bolus and 31% in the SSI group (P , 0.001).
There were reductions with basal-bolus as compared with SSI in the composite outcome [24.3
and 8.6%; odds ratio 3.39 (95% CI 1.50–7.65); P = 0.003]. Glucose ,70 mg/dL was reported in
23.1%ofpatientsinthebasal-bolusgroupand4.7%intheSSIgroup(P,0.001),buttherewere
no signiﬁcant differences in the frequency of BG ,40 mg/dL between groups (P = 0.057).
CONCLUSIONS—Basal-bolus treatment with glargine once daily plus glulisine before meals
improved glycemic control and reduced hospital complications compared with SSI in general
surgery patients. Our study indicates that a basal-bolus insulin regimen is preferred over SSI in
the hospital management of general surgery patients with type 2 diabetes.
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P
atients with diabetes are more likely
to undergo surgery than people
without diabetes (1). Surgery in di-
abetic patients is associated with longer
hospital stay, greater perioperative mor-
bidity and mortality, and higher health
care resource utilization than nondiabetic
subjects (1,2). Increased morbidity and
mortality in diabetic patients relates in
parttohigherincidenceofcomorbidcon-
ditions including coronary heart disease,
hypertension, and renal insufﬁciency
(1,3,4),aswellasadverseeffectsofhyper-
glycemia on clinical outcome (5,6). The
strongest evidence that hyperglycemia
worsensoutcomesisfromcardiacsurgery
and critically ill patients admitted to sur-
gical intensive care units (ICU) (7–9). In
this setting, observational and prospec-
tive clinical trials have shown that hyper-
glycemiaisassociatedwithincreasedrates
of hospital complications and mortality
(8,10,11) and that improved glycemic
control reduces multiorgan failure, sys-
temic infections, and short- and long-
term mortality (7,8).
Several observational studies in gen-
eral surgery patients admitted to noncrit-
ical care areas have also shown that
hyperglycemia is associated with in-
creased risks of perioperative complica-
tions, length of stay, and mortality
(12–14). Despite the increased risk of
perioperative complications, hyperglyce-
mia is frequently overlooked and inade-
quately addressed because of fear of
hypoglycemia (9,15). In the presence of
alterednutritionduringtheperioperative
period, outpatient antidiabetic regimens
are frequently held while initiating slid-
ing scale regular insulin (SSI) coverage, a
practice associated with limited thera-
peutic success (16,17). Reports from ac-
ademic institutions have shown that
most patients are treated with SSI and
that basal insulin is prescribed in less
than half of patients (18). We recently
reported that in general medicine pa-
tients with type 2 diabetes mellitus,
treatment with basal-bolus insulin regi-
men improvedglycemic control without
increasing the risk of severe hypoglyce-
mia compared with NPH and regular
insulintwicedaily(19)andwithSSIreg-
imen (20). However, no previous pro-
spective randomized trials evaluated the
optimal management of hyperglycemia
inpatientsundergoinggeneralsurgery.Ac-
cordingly,thisstudycomparedtheefﬁcacy
and safety of a basal-bolus insulin regimen
and SSI in general surgery patients with
type 2 diabetes mellitus.
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ORIGINAL ARTICLERESEARCH DESIGN AND
METHODS—Adult patients admitted
to undergo general elective or emergency
surgery and not expected to require ICU
admission were eligible for inclusion. We
enrolled patients with a blood glucose
(BG) level between 140 mg/dL and 400
mg/dL who had a history of diabetes for
more than 3 months, aged 18–80 years
old,treatedwithdietalone,anycombina-
tion of oral antidiabetic agents, or low-
dose insulin therapy at a daily dose
#0.4 units/kg before admission. Exclu-
sion criteria included hyperglycemia
without a known history of diabetes, car-
diac surgery, clinically relevant hepatic
disease orimpaired renalfunction (serum
creatinine $ 3.0 mg/dL), history of dia-
betic ketoacidosis (21), pregnancy, and
any mental condition rendering the sub-
ject unable to give informed consent.
This study was conducted at Grady
Memorial Hospital, a community teach-
inghospital;EmoryUniversityHospital,a
tertiary referral academic institution; and
the Veterans Administration Medical
Center, agovernment healthcare teaching
hospital in Atlanta, Georgia. The study
protocol and consent were approved by
the institutional review boards at Emory
University. Treatment assignment was
coordinated by a research pharmacist at
each institution following a computer-
generated block randomization table. All
patients were managed for medical and
surgical problem(s) by their primary care
team who received a copy of the assigned
treatment protocol. Management of the
insulin regimen was directed by the study
team. A teaching endocrinologist rounded
daily with the research team and was
available for diabetes care consultation.
Patients were contacted by telephone or
returned for an outpatient visit within
1 month after discharge to determine
the rate of infection and postoperative
complications.
The goal of insulin therapy was to
maintain fasting and premeal glucose
concentration between 100 and 140
mg/dL. Patients were randomly assigned
to receive either a basal-bolus regimen
withinsulinsglargineandglulisine(Lantus
and Apidra, Sanoﬁ-Aventis) or to SSI with
regular(NovolinR,NovoNordisk)insulin.
Oral antidiabetic drugs were discontinued
on admission. Patients treated with basal-
bolus therapy were started at a total daily
dose (TDD) of 0.5 units/kg divided half
as insulin glargine once daily and the
other half as insulin glulisine given before
meals.Ifapatientwasnotabletoeat,insulin
glargine was given but insulin glulisine was
held until meals were resumed. The in-
sulin TDD was reduced to 0.3 units/kg in
patients $70 years of age and/or with a
serum creatinine $2.0 mg/dL. Patients
randomizedtoSSIreceivedregularinsulin
four times daily for BG .140 mg/dL. The
doses of insulin were adjusted according
toaprespeciﬁedprotocol(Supplementary
Table 1). For subjects receiving SSI, if the
mean daily BG level was .240 mg/dL,
or if three consecutive values were
.240 mg/dL on the maximal sliding
scale dose, patients were switched to
basal-bolus regimen starting at a TDD of
0.5 units/kg.
Outcome measures
The primary outcomes of the study were
differences between treatment groups in
mean daily BG concentration and a com-
posite of postoperative complications in-
cluding wound infection, pneumonia,
bacteremia, respiratory failure, and acute
renal failure. Secondary outcomes in-
cluded differences between treatment
groups in any of the following measures:
occurrence of mild and severe hypogly-
cemia (,70 mg/dL and ,40 mg/dL,
respectively), length of hospital stay, sur-
gical complications (wound infection and
dehiscence, bacteremia, pneumonia, and
acute renal failure deﬁned as an increased
in serum creatinine .50% of baseline
and/or a serum creatinine .2.5 mg/dL),
admission to the ICU, and death.
Statistical analysis
The baseline and outcome variables were
compared with the use of Wilcoxon tests
and x
2 tests (or Fisher exact test) as
appropriate. Power calculation was con-
ducted based on our previous RABBIT 2
medicine study (19), which showed a
mean daily BG difference of .30 mg/dL
between basal-bolus with insulin analog
versus SSI regimens. Assuming a within-
group standard deviation of 40 mg/dL
and a-error rate of 5% and a ,10% attri-
tion rate, we estimated that 104 subjects
per group were needed to achieve 90%
power. Statistical analysis was performed
Table 1—Clinical characteristics on admission, type of surgery, and blood glucose values
during treatment
All SSI
Basal-bolus
insulin P value
Number of patients 211 107 104 NS
Male/female 107/104 53/54 54/50 NS
Race (white/black/other) 75/117/19 40/59/8 35/58/11 NS
Age (years) 58 6 11 57 6 10 58 6 12 NS
BMI (kg/m
2) 31.3 6 8.0 32.2 6 8.5 30.3 6 7.4 NS
Body weight (kg) 90.5 6 24.1 93.1 6 25.6 87.9 6 22.2 NS
Duration diabetes mellitus (years) 6.5 6 6.3 6.8 6 6.3 6.3 6 6.2 NS
Serum creatinine (mg/dL) 0.9 6 0.3 0.9 6 0.3 1.0 6 0.3 NS
Diabetic treatment on admission
Diet alone 17 11 6 NS
Oral agents 153 80 73 NS
Insulin alone 22 11 11 NS
Insulin + oral agents 20 11 9 NS
Type of surgery
Cancer 76 40 36 NS
Gastrointestinal/genitourinary benign 59 28 31 NS
Vascular 31 15 16 NS
Trauma 38 20 18 NS
Others 7 5 2 NS
BG values
Admission (mg/dL) 190 6 92 184 6 80 197 6 104 NS
Randomization 198 6 54 194 6 56 202 6 51 NS
Presurgery (mg/dL) 178 6 71 181 6 72 174 6 70 NS
Postsurgery (mg/dL) 198 6 53 195 6 52 201 6 55 NS
After 2nd day of Rx 159 6 42 172 6 46 145 6 32 ,0.001
BG values after 24-h treatment, % readings
,140 mg/dL 41.9 6 30.9 31.2 6 28 52.9 6 30.1 ,0.001
70–140 mg/dL 41.6 6 30.3 31.7 6 28.1 51.8 6 29.2 ,0.001
.180 mg/dL 28.1 6 30.7 35.3 6 33.5 20.5 6 25.5 ,0.001
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Cary, NC). A P value of ,0.05 was con-
sideredsigniﬁcant.Thedataarepresented
as means 6 SD.
RESULTS—From February 2008 to
October 2009, 234 patients consented
to participate. Of them, 23 patients were
excluded after randomization because
they received ,24 h of insulin treatment
(n = 14), treatment with continuous in-
sulin infusion during parenteral nutrition
(n = 3), consent withdrawal (n =3 ) ,o r
cancelled surgery (n = 3). A total of 104
patients in the basal-bolus regimen and
107 patients in the SSI group were in-
cluded in analysis (Supplementary Fig.
1). Of them, 105 patients were recruited
at Grady Memorial Hospital, 101 patients
at Emory University Hospital, and ﬁve
patients at the Veterans Administra-
tion Medical Center. The groups were
well matched, because the characteris-
tics of the patients did not differ on sex,
age, racial distribution, BMI, or duration
of diabetes (Table 1). On admission,
17.1% of patients were treated with
diet alone, 63% with oral agents alone,
9.5% with combination of oral agents
and insulin, and 10.4% with insulin
alone.
The mean admission glucose for the
entire cohort was 190 6 92 mg/dL and
the mean A1C was 7.72 6 2.2%. The
mean admission BG and A1C concentra-
tion in the basal-bolus group (197 6 104
mg/dL, A1C 8.08 6 2.4%) were higher
than in SSI group (184 6 80 mg/dL
and 7.38 6 1.9%, respectively), but dif-
ferences did not reach statistical signiﬁ-
cance (P = 0.548 and P = 0.070). The
mean BG at randomization in the basal-
bolus group was 202 6 51 mg/dL and in
the SSI group was 194 6 56 mg/dL, and
the mean glucose before surgery was
178 6 71 mg/dL and increased to
198 6 53 after surgery (P , 0.001) with
similar rise in glucose in both groups.
Patientstreatedwithinsulinglargineand
glulisine had better glycemic control than
SSI (P , 0.01) (Fig. 1A). When compared
withSSIregimen,treatmentwithbasal-bolus
insulin resulted in signiﬁcantly lower
mean fasting glucose (155 6 37 mg/dL vs.
165 6 40 mg/dL; P = 0.037) and mean
daily glucose during the hospital stay
(157 6 32 mg/dL vs. 176 6 44 mg/dL;
P , 0.001). The mean BG level after the
1st day of therapy was 145 6 32 mg/dL in
glargine/glulisine group and 172 6 47
mg/dL in SSI group (P , 0.01). The per-
centages of glucose readings ,140 mg/dL
were higher in basal-bolus than in SSI
treatment group (53 6 30 vs. 31 6
28%; P , 0.001).
Premeal glucose levels before meals
and at bedtime were signiﬁcantly higher
in the SSI group compared with basal-
bolus regimen (Fig. 1B). In addition, 13
patients (12%) treated with SSI remained
with persistent hyperglycemia (BG .240
mg/dL) despite increasing the SSI dose
to the maximal or insulin-resistant scale
(Supplementary Fig.2). Glycemiccontrol
in the SSI failure subjects rapidly im-
proved after they were switched to basal-
bolus regimen. SSI failure subjects had a
higher mean admission glucose (242 6
95 mg/dL vs. 175 6 74 mg/dL; P = 0.127)
and developed wound infection at a
higher rate (30.8 vs. 7.5%; P = 0.027).
Difference between groups in the
frequency of the composite outcome in-
cluding wound infection, pneumonia,
bacteremia, respiratory failure, and acute
renal failure were higher in the SSI group
(24.3%)thaninbasal-bolusgroup(8.6%;
P = 0.003) (Table 2). There were reduc-
tions with basal-bolus as compared with
SSIinwoundinfection(2.9vs.10.3%;P=
0.05),pneumonia(0vs.2.8%;P=0.247),
and acute renal failure (3.8 vs. 10.3%; P =
0.106). In addition, the basal-bolus regi-
men resulted in lower but not signiﬁcant
reduction in postsurgical ICU admis-
sions. A total of 13 out of 104 patients
Figure 1—A: Glucose levels during basal-bolus and SSI treatment. Changes in blood glucose
concentration after the 1st day of treatment with basal-bolus with glargine once daily plus glu-
lisine before meals (○) and with SSI 4-times daily (●). *P , 0.001, ŧP =0 . 0 2 ,†P =0 . 0 1 .
B: Glucose levels before meals and bedtime. Premeal and bedtime glucose levels were higher
throughout the day in the SSI group (●) compared with basal-bolus regimen (○).
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and 21 out of 107 patients treated with
SSI (19.6%) required admission to the
ICU (P = 0.16). The length of ICU stay
was shorter in patients treated with basal-
bolus insulin compared with SSI group
(3.19 6 2.14 vs. 1.23 6 0.60; P =0 . 0 0 3 ) .
There were no differences in hospital
length of stay (9.4 6 12.8 vs. 9.1 6 6.8
days;P=0.25)orinmortality(onepatient
in each arm) between groups.
The average total insulin use after
24-h treatment was 33.4 units/day in the
basal-bolus group and 12.3 units/day in
the SSI group (P , 0.001). For the basal-
bolus group, after 24-h treatment, the
mean dose of insulin glargine was
21.8 6 8.6 units/day and of glulisine
was 14.8 6 7.6 units/day, and the mean
supplemental (correction) dose was
8.7 6 4.4 units/day. Patients treated
with SSI received a mean daily dose of
12.3 6 6.5 units of regular insulin (range
9.7 to 14.4 units) after 24-h treatment,
with 88.5% of patients receiving less
than 20 units and 39.4% receiving less
than 10 units per day.
Hypoglycemia (,70 mg/dL) oc-
curred in 23.1% of patients in the basal-
bolus and 4.7% of patients in the SSI
treated group (P , 0.001) (Table 3).
Severe hypoglycemia (,40 mg/dL) was
reported in 3.8% of patients in the
basal-bolus and none in the SSI group
(P = 0.057). There were no differences
in the frequency of hypoglycemia be-
tween patients treated with insulin before
admission compared with insulin-naïve
patients. A glucose ,70 and ,40 mg/dL
was observed in 11.9 and 4.8% of those
treatedwith insulin before admissioncom-
pared with 11.8 and 1.2% of insulin-naïve
patients.
Atotalof15patients.70yearsofage
or with a serum creatinine .2m g / d L
were treated with an initial TDD of 0.3
unit/kg. When compared with patients
treated with an initial TDD of 0.3 unit/kg,
patients receiving 0.5 unit/kg had no
differences in mean daily BG (159 6 33
mg/dLand147625mg/dL,respectively;
P = 0.19) or in the frequency of hypogly-
cemicevents(23.6and 20.0%;P.0.99).
Inaddition,18patients(8.5%)werestarted
on insulin before surgery (mean 6 SD
3.8 6 5 days; median 1.5 days) and 193
patients(91.5%)werestartedthedayofor
after surgery (mean 6 SD 1.6 6 1 days;
median 1 day). When compared with pa-
tients treated with insulin before surgery,
those who received insulin after surgery
had no signiﬁcant differences in the
mean daily BG (166.7 6 40.5 mg/dL vs.
163.9 6 29.6 mg/dL; P = 0.93) or in the
frequency of hypoglycemic events (14.0
vs. 11.1%; P . 0.99).
CONCLUSIONS—This prospective,
randomized clinical trial compared the
glycemic efﬁcacy and safety of a basal-
bolus regimen with insulin glargine once
daily and insulin glulisine before meals to
SSIingeneralsurgery patientswithtype2
diabetesmellitus.Weobservedthatbasal-
bolus treatment signiﬁcantly improved
glycemic control measured as mean daily
glucose concentration after the 1st day of
therapy and reduced perioperative com-
plications observed as the composite of
postoperative complications including
wound infection,pneumonia,bacteremia,
respiratory failure, and acute renal failure.
We conclude that basal-bolus insulin
regimen is preferred over SSI in the hos-
pital management of general surgery pa-
tients.
The association between hypergly-
cemia and increased risk of hospital
complications and mortality is well es-
t a b l i s h e di nI C Ua n dc a r d i a cs u r g e r y
patients (7–9). In non-ICU patients, small
observationalstudieshavealsoshownthat
perioperative hyperglycemia is associated
withincreasedriskofinfectiouscomplica-
tions and mortality (13,14). General sur-
gery patients with glucose levels of .12.2
mmol/L (.220 mg/dL) on the ﬁrst post-
operative day had a 2.7 times increased
rate of infection (13). Another study re-
ported that patients with glucose levels
of 5.6–11.1 mmol/L (110–200 mg/dL)
and those with glucose levels of .11.1
mmol/L had, respectively, 1.7-fold and
2.1-fold increased mortality compared
with those with glucose levels ,5.6
mmol/L(13).Mostpatientswithdiabetes
admitted to general surgery service have
poorglycemiccontrol,anddiabetesman-
agement is frequently overlooked (6,22).
In the presence of altered nutrition,
Table 2—Composite hospital complications and outcomes composite hospital complications
All SSI
Basal-bolus
insulin P value
Wound infections 14 11 3 0.050
Pneumonia 3 3 0 0.247
Acute respiratory failure 6 5 1 0.213
Acute renal failure 15 11 4 0.106
Bacteremia 3 2 1 0.999
Number of patients with complications 35 26 9 0.003
Mortality 2 1 1 NS
Postsurgery ICU admission (%) 16 19.6 12.5 NS
Length of stay (days)
ICU 2.51 6 1.90 3.19 6 2.14 1.23 6 0.60 0.003
Hospital 6.8 6 8.9 6.3 6 5.6 7.23 6 11.39 NS
Table 3—Hypoglycemic events
Variable All SSI
Basal-bolus
insulin P value
Number of patients 211 107 104
Number of BG tests 3,778 1,826 1,952
BG ,40 mg/dL
Number of patients (%) 4 (3.8) 0 (0) 4 (3.8) 0.057
Number of events 4 0 4
Number of readings (%) 0.10 0 0.20
BG ,60 mg/dL
Number of patients (%) 14 (6.6) 2 (1.9) 12 (11.5) 0.005
Number of events 17 2 15
Number of readings (%) 0.45 0.11 0.77
BG ,70 mg/dL
Number of patients (%) 29 (0.8) 5 (4.7) 24 (23) ,0.001
Number of events 44 6 38
Number of readings (%) 1.16 0.33 1.95
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antidiabetic regimen and initiate sliding
scale insulin coverage (16,17,23). The
University Health System Consortium
Benchmarking Project (24), an alliance
of 90 academic health centers across
theU.S.,showedthatin thenon-ICUset-
ting, subcutaneous insulin therapy was
prescribed only in 45% of patients,
with a range of 12–77% across measured
hospitals.
We recently reported the results of
the RABBIT 2 medicine trial, a prospective
multicentertrialcomparingtheefﬁcacyand
safety of a basal-bolus insulin regimen with
glargine and glulisine insulin and SSI in
insulin-naïve patients with type 2 diabetes
mellitus admitted to general medicine
wards (20). We achieved a glucose target
of ,140 mg/dL in 55% of patients in the
basal-bolus and31% intheSSI group(P ,
0.001). The results of the RABBIT surgery
trial also indicate that a basal-bolus insulin
regimenismoreeffectivethanSSIingeneral
surgerypatients.Inaddition,weobserveda
signiﬁcantreductionbetweengroupsinthe
frequency of the composite outcome in-
cluding wound infection, pneumonia, bac-
teremia, respiratory failure, and acute renal
failure. Taken together, these two studies
indicate that a basal-bolus insulin regimen
is preferable over SSI in medical and surgi-
cal patients with type 2 diabetes mellitus
and clearly indicate that SSI alone should
notbeusedinthemanagementofhospital-
ized subjects with diabetes.
The basal-bolus regimen with glar-
gine once daily and glulisine before meals
at astarting dose of0.3–0.5unit/kg/dayis
well tolerated with an acceptable rate of
hypoglycemia. In the RABBIT medicine
trial, only two patients (3%) in the glar-
gineandglulisinegroupexperiencedaBG
,60 mg/dL and no patients had a value
,40 mg/dL. In this RABBIT surgery
trial, a glucose ,70 mg/dL was reported
in 23.1% of patients (1.9% of glucose
readings) in the basal-bolus and in 4.7%
(0.3% of readings) in the SSI group (P =
,0.001), but there were no signiﬁcant
differences in the frequency of severe hy-
poglycemia. Differences in hypoglycemic
events between the two trials could be in
part explained by reduced nutritional in-
take in surgical patients and the fact that
in the previous trial we dosed the TDD of
insulin as 0.4 units/kg for BG between
140 mg/dL and 200 mg/dL and 0.5 unit/
kg for BG between 200 mg/dL and ,400
mg/dL. In the RABBIT surgery trial most
patientsreceived a singledaily dose of 0.5
units/kg.
We acknowledge the following limita-
tions in this study. We excluded patients
undergoing cardiac surgery or in need for
ICU care and with clinically relevant he-
paticdiseaseorwithserumcreatinine$3.0
mg/dLandhistoryofhyperglycemiccrises.
In addition, we limited the recruitment to
patients treated with diet, oral antidiabetic
agents, and a low-dose insulin therapy and
excluded patients receiving a TDD .0.4
unit/kg per day before admission. In such
patients, higher insulin doses may be
neededtoachieveglycemiccontrol.Alarge
prospective, multicenter, randomized clin-
ical trial of glycemic control in general sur-
gery setting is certainly needed to address
theseimportantissues.Suchstudiesshould
include additional treatment regimes com-
paring basal insulin alone (glargine, dete-
mir, or NPH) and basal-bolus regimens in
surgical patients with type 2 diabetes.
In summary, basal-bolus insulin with
glargine once daily plus glulisine before
meals represents a simple and an effective
regimen for the management of general
surgery patients with type 2 diabetes mel-
litus. The basal-bolus regimen isassociated
with better glycemic control and lower
frequency of hospital complications than
SSI, without increasing the number of
severe hypoglycemic events. These results
indicate that a basal-bolus insulin regimen
should be preferred over SSI treatment in
general surgery patients and that SSI alone
should not be used in the management of
hospitalized subjects with diabetes.
Acknowledgments—Thisinvestigator-initiated
study was supported by an unrestricted grant
from sanoﬁ-aventis (Bridgewater, NJ). G.E.U.
is supported by American Diabetes Association
ResearchGrant 7-03-CR-35, National Institutes
ofHealth(NIH)GrantR03-DK-073190-01,and
General Clinical Research Center Grant M01
RR-00039. D.S. is supported by NIH Research
Grant K12-RR-017643.
No other potential conﬂicts of interest rel-
evant to this article were reported.
Thesponsorsofthestudywerenotinvolved
in the study design, data collection, analysis,
or interpretation of the results or preparation
of the article.
G.E.U., D.S., S.J., L.P., A.T., P.M., D.U.,
C.N., D.O., and M.R. researched the data.
G.E.U., D.S., S.J., L.P., C.N., D.O., and M.R.
also reviewed and edited the manuscript and
contributed to the discussion. G.E.U. wrote
the primary portion of the manuscript.
References
1. ClementS,BraithwaiteSS,MageeMF,etal;
American Diabetes Association Diabetes in
Hospitals Writing Committee. Manage-
ment of diabetes and hyperglycemia in
hospitals. Diabetes Care 2004;27:553–591
2. Smiley DD, Umpierrez GE. Perioperative
glucosecontrolinthediabeticornondiabetic
patient. South Med J 2006;99:580–591
3. LazarHL,ChipkinSR,FitzgeraldCA,BaoY,
Cabral H, Apstein CS. Tight glycemic con-
trol in diabetic coronary artery bypass graft
patients improves perioperative outcomes
and decreases recurrent ischemic events.
Circulation 2004;109:1497–1502
4. Ramos M, Khalpey Z, Lipsitz S, et al. Re-
lationship of perioperative hyperglycemia
and postoperative infections in patients
who undergo general and vascular sur-
gery. Ann Surg 2008;248:585–591
5. Risum O, Abdelnoor M, Svennevig JL,
et al. Diabetes mellitus and morbidity and
mortality risks after coronary artery by-
pass surgery. Scand J Thorac Cardiovasc
Surg 1996;30:71–75
6. Umpierrez GE, Isaacs SD, Bazargan N,
You X, Thaler LM, Kitabchi AE. Hyper-
glycemia: an independent marker of
in-hospital mortality in patients with
undiagnoseddiabetes.JClinEndocrinol
Metab 2002;87:978–982
7. Furnary AP, Gao G, Grunkemeier GL,
et al. Continuous insulin infusion reduces
mortality in patients with diabetes un-
dergoing coronary artery bypass grafting.
J Thorac Cardiovasc Surg 2003;125:1007–
1021
8. van den Berghe G, Wouters P, Weekers F,
et al. Intensive insulin therapy in the
critically ill patients. N Engl J Med 2001;
345:1359–1367
9. InzucchiSE.Clinicalpractice.Management
of hyperglycemia in the hospital setting.
N Engl J Med 2006;355:1903–1911
10. VandenBergheG,WilmerA,HermansG,
et al. Intensive insulin therapy in the
medical ICU. N Engl J Med 2006;354:
449–461
11. Kitabchi AE, Freire AX, Umpierrez GE.
Evidenceforstrictinpatientbloodglucose
control: time to revise glycemic goals in
hospitalized patients. Metabolism 2008;
57:116–120
12. Turnbull PJ, Sinclair AJ. Evaluation of
nutritionalstatus and its relationship with
functional status in older citizens with
diabetes mellitus using the mini nutri-
tional assessment (MNA) tool—ap r e l i m -
inary investigation. J Nutr Health Aging
2002;6:185–189
13. Pomposelli JJ, Baxter JK 3rd, Babineau TJ,
et al. Early postoperative glucose control
predicts nosocomial infection rate in di-
abetic patients. JPEN J Parenter Enteral
Nutr 1998;22:77–81
14. Noordzij PG, Boersma E, Schreiner F,
etal.Increasedpreoperativeglucoselevels
are associated with perioperative mortal-
ity in patients undergoing noncardiac,
nonvascular surgery. Eur J Endocrinol
2007;156:137–142
260 DIABETES CARE, VOLUME 34, FEBRUARY 2011 care.diabetesjournals.org
RABBIT surgery trial15. Malouf R, Brust JC. Hypoglycemia: causes,
neurological manifestations, and outcome.
Ann Neurol 1985;17:421–430
16. Gearhart JG, Duncan JL 3rd, Replogle
WH, Forbes RC, Walley EJ. Efﬁcacy of
sliding-scale insulin therapy: a compari-
son with prospective regimens. Fam Pract
Res J 1994;14:313–322
17. Hirsch IB. Sliding scale insulin—time
to stop sliding. JAMA 2009;301:213–
214
18. Schnipper JL, Barsky EE, Shaykevich S,
Fitzmaurice G, Pendergrass ML. Inpatient
managementofdiabetesandhyperglycemia
among general medicine patients at a
largeteachinghospital.JHospMed2006;
1:145–150
19. Umpierrez GE, Hor T, Smiley D, et al.
Comparison of inpatient insulin regimens
with detemir plus aspart versus neutral
protamine hagedorn plus regular in medi-
cal patients with type 2 diabetes. J Clin
Endocrinol Metab 2009;94:564–569
20. Umpierrez GE, Smiley D, Zisman A, et al.
Randomized study of basal-bolus insulin
therapy in the inpatient management of
patients with type 2 diabetes (RABBIT 2
trial). Diabetes Care 2007;30:2181–2186
21. Kitabchi AE, Umpierrez GE, Murphy MB,
Kreisberg RA. Hyperglycemic crises in
adult patients with diabetes: a consensus
statement from the American Diabetes As-
sociation. Diabetes Care 2006;29:2739–
2748
22. Levetan CS, Magee MF. Hospital man-
agement of diabetes. Endocrinol Metab
Clin North Am 2000;29:745–770
23. UmpierrezG,MaynardG.Glycemicchaos
(not glycemic control) still the rule for
inpatient care: how do we stop the in-
sanity? J Hosp Med 2006;1:141–144
24. BoordJB,GreevyRA,BraithwaiteSS,etal.
Evaluation of hospital glycemic control at
US academic medical centers. J Hosp Med
2009;4:35–44
care.diabetesjournals.org DIABETES CARE, VOLUME 34, FEBRUARY 2011 261
Umpierrez and Associates